First Patient Enrolls in Study of NAC for Targeted Treatment in IPF

First Patient Enrolls in Study of NAC for Targeted Treatment in IPF

282568

First Patient Enrolls in Study of NAC for Targeted Treatment in IPF

The first patient has enrolled in a Phase 3 clinical trial testing whether N-acetyl cysteine (NAC), an antioxidant, can be a targeted treatment for a subset of idiopathic pulmonary fibrosis (IPF) patients with a particular gene variant. The trial, called PRECISIONS (Prospective tReatment EffiCacy in IPF uSIng genOtype for Nac Selection) and supported by the Pulmonary Fibrosis Foundation (PFF), is the first to apply the principles of precision medicine to IPF, according to a PFF press…

You must be logged in to read/download the full post.